Allogene Moves Forward With CAR-T Therapy Pipeline – Seeking Alpha

Allogene Therapeutics (ALLO) has a pipeline full of immunotherapy products it is developing to treat different types of cancer. Specifically, its platform relies on allogeneic CAR-T therapies. The latest partnership involves Notch Therapeutics and its own technology platform to treat cancer. Both companies will develop induced pluripotent stem cell (iPSC) AlloCAR therapy products using Notch's technology. This will help diversify Allogene's pipeline and give it access to treat a few types of hematological malignancies.

Allogene Therapeutics has formed a worldwide collaboration and license agreement with Notch Therapeutics. This agreement was made so that both companies could research and develop iPSC AlloCAR therapy products to treat a few types of hematological malignancies. Such hematological malignancies include: Non-Hodgkin lymphoma (NHL), leukemia, and multiple myeloma (MM). The development of the iPSC AlloCAR therapy products using either T-cells or natural killer cells will be done using Notch's Engineered Thymic Niche (ETN) platform. Why has Allogene chosen to make such a partnership? There are many advantages to tapping into the ETN platform. First and Foremost, pluripotent stem cells provide an inexhaustible source. Meaning an inexhaustible source that could be used as any cell type to treat a variety of diseases. That's just one advantage this technology has. Further advantages for this type of technology include lower cost of manufacturing such treatments and larger industrial scale. There is something even more important on why I believe such a partnership was made. While both companies are targeting a few hematological malignancies, iPSC AlloCar therapy products could also be utilized for other indications such as: Aging, autoimmune diseases, and infectious diseases. If early evidence seems promising in hematological malignancies, then I believe there will be a great interest to explore this technology in other areas. Under the terms of the agreement, Notch will first focus on taking care of the preclinical work with respect to the iPSC AlloCAR T cells. Allogene will work on the products when they get to the clinical stage and obtain exclusive worldwide rights to commercialize them. Notch doesn't go home empty-handed though. It obtains some perks as well, like:

The point here is that Allogene gains access to a technology that prides itself on providing a renewable source cell type of a product that could change the scope of CAR-T treatment.

According to the 10-Q SEC Filing, Allogene Therapeutics has cash, cash equivalents, and investments of $601.9 million as of September 30, 2019. The company believes that it has enough cash on hand to fund its operations for at least 12 months from the date of the 10-Q SEC Filing. Since this was filed on November 5, 2019, this means cash will run out sometime by November 5, 2020. Although, biotechs don't wait until the end of their estimates to raise additional cash. I would say that the biotech may need to raise cash sometime during mid-2020. The company has a lot of cash on hand because of the IPO it had done back in October of 2018. At that time, it has been the largest biotech IPO established in 2018. That's because it raised a total of $343.3 million in net proceeds.

Allogene has its own CAR-T technology it utilizes to develop treatments for cancer. Specifically, it has a huge focus on developing allogeneic CAR-T therapy treatments. The advantage of allogeneic is being able to produce treatment for cancer patients at a quicker rate compared to autologous therapy. For allogeneic CAR-T treatment, it is considered to be "off the shelf" therapy. Meaning patients won't have to wait for treatment. That's because, with autologous therapy, cells from the patient have to be extracted first, engineered, and then delivered back into the patient. This process takes about 4 weeks. On the other hand, for allogeneic CAR-T therapy, the treatment is ready to go and just needs to be administered to the patient. As with most CAR-T companies, Allogene is heavily focused on hematological malignancies (blood cancer). However, it won't just leave it to its own products in the pipeline to advance drugs in the clinic for hematological malignancies. That's why it has also chosen to partner with Notch Therapeutics for its iPSC AlloCAR therapy products. The key advantage being that Notch's technology provides an inexhaustible source of cells to utilize. A big risk for the partnership is that it will take some time to get this program into clinical trials in humans. In addition, there is no guarantee that this program will ultimately succeed in late-stage studies. Having said that, I believe that this will help Allogene expand the market opportunity in the hematology space. Especially, since the CAR-T therapy space is quite crowded when it comes to treating hematological malignancies.

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Visit link:
Allogene Moves Forward With CAR-T Therapy Pipeline - Seeking Alpha

Texan Spending Fortune, Hours A Day Trying To Live To At Least 120 Years Old: I Am My Asset – CBS Dallas / Fort Worth

DALLAS (CBSDFW.COM) Hundreds of pills, expensive machines and constant blood testing.

They are among the keys to immortality according the ultra-wealthy who are becoming devout followers of whats known as biohacking.

A rich Dallas and Austin developer is offering CBS 11 News a rare glimpse into the lifestyle.

Ari Rastegar (CBS 11)

Ari Rastegar goes to bed in special clothing on a temperature-regulated bed.

It has this metallic mechanism inside of it that helps flush lactic acid and eliminate inflammation, says Rastegar.

He also wears a mask.

Orange glasses that illuminate the the light so I dont disrupt the circadian rhythms, he says.

Thats just Rastegars nightly routine.

During the day, he takes nearly 150 vitamins customized to his current needs by his doctor.

Rastegar also gets his blood tested monthly.

The 37-year-old has a $15,000 vapor machine thats supposed to reduce stress and another $15,000 machine designed to calm his brain two hours before bedtime.

He says its paying off and making him healthier than ever.

I am my asset, he says.

Ari Rastegar and his vapor machine. (CBS 11)

Biohacking is all part of an effort to extend life beyond anything humans can imagine.

The data will tell you the folks that are living this type of lifestyle are living well in excess of 120 years old, says Rastegar.

The goal of biohacking is to keep strands of DNA from aging.

Rastegar has already spent hundreds of thousands of dollars.

But the real estate developer can afford it with the money he makes as CEO of Rastegar Property.

He owns buildings in Austin and is planning a $100,000,000, 26-story residential tower in the uptown section of Dallas next year.

I dont know if Im trying to live forever. Im trying to live as long as I can contribute, he says.

Rastegars exhausting daily routine also includes a hyperbaric chamber, meditation and he employs a life coach.

Rastegar is one of a growing number of longevity devotees who also undergo hormone therapy.

Others, not Rastegar, have even resorted to blood transfusions and stem cell treatments stay young.

My biological age is now that of about a 4-year-old, he says.

But medical doctors say not so fast when it comes to treatments that promise to slow down aging.

We dont have any long-term evidence-based studies to correlate whatever biohacking techniques people are using to prolong or extend life, yet, says Dr. James Pinckney of Diamond Physicians.

While physicians are cautious, Rastegar says hes seen the proof by lowering his cholesterol and raising his testosterone.

Rastegar along with a number of other millionaires and billionaires are spending vast amounts of their fortunes in the search for immortality.

But he says that doesnt mean he fears death.

I think were all little bit apprehensive, he says. I like to focus more on living, even with all this biohacking and all this stuff you dont know if youre going to make it to the next day.!

Read the original:
Texan Spending Fortune, Hours A Day Trying To Live To At Least 120 Years Old: I Am My Asset - CBS Dallas / Fort Worth

Heart-warming moment OAP meets mum who saved his life with anonymous stem cell donation after three years of – The Sun

THIS is the heart-warming moment a pensioner met the mum who saved his life with her anonymous stem cell donation after travelling 2,300 miles to thank her in person.

Jackie Wray, 50, met with her genetic twin, Siegfried Siggi Wahl, 71, in September after the pair spent more than three years communicating anonymously due to the laws surrounding stem cell donations.

9

9

9

Siggi, from Hattersheim in Germany, was diagnosed with chronic myeloid leukaemia in April 2015 after he had suffered a stroke and doctors found the cancer when he was hospitalised.

After initial treatment proved unsuccessful, doctors told Siggi that his best chance of survival was a blood stem cell donation from a person with identical tissue type.

Luckily, just six months earlier, Siggis genetic twin Jackie, from, had signed up with blood cancer charity DKMS in 2015 after seeing a TV appeal for a child in urgent need of a donor.

And this moving video captures the moment Siggi met his angel Jackie at her home in Great Ayton, Middlesbrough for the first time earlier this year.

Jackie, who runs a wedding venue, said: Six months after being on the donor register, doctors had found a match I knew nothing about him at this stage, just that he was a man in Germany.

During the process, we both wanted to send cards to each other to check that each of us was alright, and I found out more information about him that way.

Jackie explained that donating her stem cells was like giving blood and lasted around four to five hours.

As a courier arrived to escort Jackies blood stem cells from London to Frankfurt, news broke of the 2016 terrorist attack in Paris, France, and the courier was unable to leave the UK.

9

9

As Siggis wife Ursula sat at his bedside, doctors were worried the blood stem cells would not get to Siggi in time.

Dad-of-two Siggi said: The terrorist attack in France that delayed the stem cell courier shocked me and my wife, who was sitting next to my hospital bed with many tears in her eyes.

The next day, when the doctor came into my room, and said that the courier was on his way, and I had tears of joy in my eyes.

After Jackies stem cells finally arrived in Frankfurt , the transplant immediately went ahead.At one stage, Jackie had to donate extra blood plasma to Siggi, where she went through the same process as she did when harvesting the blood stem cells.

The extra donation meant it took them three years before they could finally meet.

This is because UK law states that whilst donors and their patients can communicate following the transplant, it must remain anonymous for at least the first two years.

The day their anonymity was waived, Siggi rang up Jackie straight away after exchanging email addresses, and after a very emotional conversation, the pair arranged to meet for the first time in the UK.

Jackie invited Siggi and his wife Ursula over to her home in Middlesbrough, where they stayed for three nights.

Exclusive

SICK JOKER Russell Howard slammed by mum for mocking disabled daughter's 40k access ramp

Exclusive

HARRY'S NO-HO-HO Harry and Meghan won't join the Queen for Christmas leaving Her Maj 'hurt'

'PREYED ON' Primark guard raped & made girls, 15, perform sex acts as shoplift 'punishment'

IT CURED BE YOU! Mum gets all-clear from cancer & 10 minutes later wins 1m on EuroMillions

D-DAY HERO DEAD Lord Bramall falsely accused of child abuse by fantasist dead at 95

BOILING POINT Furious woman, 50, fined 1,500 after tirade at commuter eating 'smelly' eggs

During the trip, Siggi presented Jackie with a silver necklace with a pendant in the shape of an angel, to signify her saving his life.

Jackie said: When he arrived, there were lots of tears and lots of cuddling Siggi and his wife had made me a photo album with pictures of him during his treatment which just made me cry instantly.

Siggi added: For me, she is my angel that saved my life.

9

9

9

9

Here is the original post:
Heart-warming moment OAP meets mum who saved his life with anonymous stem cell donation after three years of - The Sun

CytoDyn Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer – GlobeNewswire

VANCOUVER, Washington, Nov. 12, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has received approval from the Institutional Review Board (IRB) for leronlimab to be administered to patients with triple-negative breast cancer (TNBC) under a compassionate use, which is also known as expanded access program.

This program will allow TNBC patients who are not eligible under the ongoing Phase 1b/2 clinical trial to receive leronlimab (PRO 140). Under this protocol, patients with locally recurrent or metastatic triple-negative breast cancer who had progressed within six months or less on latest chemotherapy will receive leronlimab (PRO 140) combined with a treatment of physicians choice.

The compassionate use or expanded access program is a potential pathway for patients with an immediately life-threatening condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. An IRB is an appropriately constituted group that has been formally designated to review and monitor biomedical research involving human subjects pursuant to regulations of the U.S. Food and Drug Administration (FDA).

We are very pleased with the confidence demonstrated by the IRB to allow access to leronlimab for patients with triple-negative breast cancer. We are dedicated to advancing this therapeutic opportunity to many more patients in our ongoing trials, stated Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn.

Expanded access may be appropriate when all the following apply:

Investigational drugs, biologics or medical devices have not yet been approved or cleared by FDA and FDA has not found these products to be safe and effective for their specific use. Furthermore, the investigational medical product may, or may not, be effective in the treatment of the condition, and use of the product may cause unexpected serious side effects.

About Leronlimab (PRO 140)The U.S. Food and Drug Administration (FDA) has granted a "Fast Track" designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with highly active anti-retroviral therapy (HAART) for HIV-infected patients, and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including non-alcoholic steatohepatitis (NASH). Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays a vital role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. CytoDyn is conducting additional research with leronlimab in the setting of oncology and NASH with plans to conduct further clinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD. Blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted "orphan drug" designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a crucial role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication, which, if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients. Some patients on leronlimab monotherapy have viral suppression for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and has received clearance to initiate a clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking StatementsThis press release contains certain forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements but, their absence does not mean that a statement is not forward-looking. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Companys cash position, (ii)the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv)the Companys ability to enter into partnership or licensing arrangements with third parties, (v)the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Companys ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Companys clinical trials, (viii)the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CONTACTSInvestors: Nader Pourhassan, Ph.D.President & CEOnpourhassan@cytodyn.com

View post:
CytoDyn Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer - GlobeNewswire

Editas and Celgene sub Juno are tackling hottest immunotherapy cells – Endpoints News

As the first CRISPR-edited cancer patients watch their treatments unfold, one of the first CRISPR companies is rejigging a major oncology deal.

Editas Medicine is amending its long-running collaboration with Celgene and their subsidiary Juno Therapeutics. The new deal will expand the focus of their work to cover a subset of immune cells that have become an increasingly hot target for immunotherapy: gamma-delta cells.

The deal will make Editas eligible for a $70 million payment along with other possible milestones and royalties.

Its a significant expansion of the deal, Editas CSO Charlie Albright toldEndpoints News. These cells are part of the immune system and have significant potential to treat solid tumors.

Since it began in 2015, the Juno-Editas collaboration has focused largely on alpha-beta cells, the ones outfitted with the special receptors in current CAR-T treatments. Scientists at those companies and elsewhere have most publicly tried to apply CRISPR to improve CAR-T, which now work solely through viral gene transfer.

But they have also worked on expanding the approach to other immune cell types in hopes of making the treatment more effective, more accessible or as is the case with some of the gamma delta research expand it into other cancer types, especially solid tumors.

Editas has been slowly building their gamma-delta base throughout the year, Albright said. In April, they signedan agreement with BlueRock, in part to access pluripotent stem cells they hope to make into engineered gamma-delta cells that can be delivered to a patient. (Essentially a form of off-the-shelf CART).

Several companies are now pursuing gamma-delta immunotherapies, including GammaDelta Therapeutics and its new spinoff Adaptate and Regeneron-backed Adicet Bio. Theyre betting chiefly on these cells ability to penetrate the solid tumors that have been so resistant to the first wave of CAR-T treatments.

Albright argued, though, that for these techniques to work you need gene editing. Innate abilities in the cells have to be tuned up, he said. You have to increase cells persistence and enhance their ability to survive in a tumors micro-environment. Ideally, he said, you even give it new abilities, such as the power to catalyze the bodys innate immune system.

You cant do that with viral transduction, Albright said. You need gene editing.

Continued here:
Editas and Celgene sub Juno are tackling hottest immunotherapy cells - Endpoints News

Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World’s First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic…

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, published updated clinical data from the ongoing phase 2a study (HEP101) of its lead product candidate HepaStem in patients with Acute-on-Chronic Liver Failure (ACLF) or acute decompensation (AD) at high risk of developing ACLF. The data were presented in an oral presentation at the Annual Meeting of the American Association for Study of Liver Diseases (AASLD) on November 10, 2019, in Boston, by Prometheras principal investigator Prof. F. Nevens, KULeuven, Belgium. The data set confirmed earlier findings presented at The International Liver Congress - ILC 2019 in April.

Currently, liver transplant is the only rescue treatment for patients suffering from ACLF and to a lesser degree for patients with acute decompensation of the liver (AD). There are no other existing therapies that can rescue the end-stage-liver failure. Promethera is developing HepaStem as an alternative to transplant; it consists of liver derived stem cells that are obtained from ethically donated healthy human organs and expanded in GMP culture conditions. These liver derived signaling stem cells migrate through the blood stream to reach the liver, where they support the tissue regeneration via their potent secretome.

In the trial HEP101, HepaStem has been intravenously infused in single or repeated injections in multiple ascending doses in patients to assess the tolerability and the safety profile of the treatment. The trial which recruited a total of 24 patients, including 16 patients with ACLF and 8 patients with AD has met its primary endpoint.

With one or two repeated doses up to 1.2 million cells per kilogram of body weight, no adverse events related to HepaStem occurred and no clinically significant changes were shown in platelet count, fibrinogen levels, and coagulation factors following HepaStem infusion. The demonstrated safety of two infusions of 1.2 million cells per kilogram of body weight provide solid guidance for conducting the subsequent trials. In addition to the positive safety profile, the study has shown trends in efficacy with improvement in three indicators of liver disease severity; Model for End Stage Liver Disease score (MELD), Child-Pugh score and bilirubin levels, 28 days and three months after treatment initiation. Promethera plans to demonstrate the efficacy of HepaStem at 1.0 million cells per kilogram of body weight in ACLF with a large multicentric double blind placebo-controlled trial (HEP102). The study HEP102 is expected to start end 2019.

We continue to pioneer the use of liver stem cells for the treatment of severe liver diseases and the updated status from the worlds first clinical trial evaluating a cell-based therapy in ACLF gives us confidence about the safety aspects and the broad therapeutic potential of our therapy, said Etienne Sokal, M.D., Ph.D., Prometheras Group Chief Medical Officer. As a potential first tangible alternative to organ transplantation for an ever-growing patient population, HepaStem will advance into a larger efficacy trial in ACLF focusing on a reduced need for transplantation and a decreased mortality.

Prof. Nevens added, With the data set having evolved since we last presented results at this years ILC Congress, the Phase 2a trial provides a strong rationale for further clinical evaluation of the therapeutic concept and has provided a safe dosing regimen which will guide future studies.

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera, HepaStem, H2stem, are all registered trademarks of the PROMETHERA group.

Read the original here:
Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World's First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic...

Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma – Hematology Advisor

According to results from a study published in Blood, the 3-drug combination of bortezomib, lenalidomide, and dexamethasone (VRD) as induction therapy prior to autologous stem cell transplant (ASCT) is highly effective at achieving and maintaining high-quality responses in patients with multiple myeloma (MM).

The findings came from the ongoing, open label, randomized, phase 3 PETHEMA/GEM2012 trial (ClinicalTrials.gov Identifier: NCT01916252), which was designed to compare transplant conditioning regimens (intravenous busulfan plus melphalan vs melphalan alone) in 458 patients who received VRD induction and consolidation for newly diagnosed, symptomatic MM.

The researchers focused on a secondary end point, depth of response (complete response [CR] and measurable residual disease [MRD]) throughout induction, ASCT, and consolidation, and evaluated safety during induction. Patients, who were 65 years or younger, were administered 6 cycles of VRD, with each 28-day cycle consisting of lenalidomide given from day 1 to 21; subcutaneous bortezomib given on days 1, 4, 8, and 11; and dexamethasone given on days 1 to 4 and 9 to 12.

After 6 induction cycles, the CR rate was 33.4% and undetectable MRD rates were 28.8% and 47.4% at median thresholds of 3 x 10-6 and 3 x 10-4, respectively. Over time, responses deepened; in patients who had started cycle 6, the rates of very good partial response or better were 55.6% by cycle 3, 63.8% by cycle 4, 68.3% by cycle 5, and 70.4% after induction. Similarly, the rates of undetectable MRD at a threshold of 3 x 10-6 increased from 28.8% after induction to 42.1% after transplant and 45.2% after consolidation.

During induction, neutropenia (12.9%) and infection (9.2%) were the most common grade 3 or higher treatment-emergent adverse events. The rate of grade 2 or higher peripheral neuropathy was 17.0% (grade 3, 3.7%; grade 4, 0.2%). Treatment was disctonued in 14 patients (3.1%), and 9 patients (2.0%) died due to treatment-emergent adverse events.

Disclosures: Some authors have declared affiliations with the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Reference

1. Rosiol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma [published online, October 17, 2019]. Blood. doi:10.1182/blood.2019000241

Read the original here:
Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma - Hematology Advisor

Global cell therapy market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 – Yahoo Finance

The report on the global cell therapy market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global cell therapy market to grow with a healthy CAGR over the forecast period from 2019-2025.

New York, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Therapy Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" - https://www.reportlinker.com/p05796546/?utm_source=GNW The study on cell therapy market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on cell therapy market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global cell therapy market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global cell therapy market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings1) Drivers Increasing incidences of cancer across the globe Growing aging patient population Rise in cell therapy transplantations2) Restraints The high cost of transplantation treatment Stringent regulatory policies3) Opportunities Automation in cell therapy

Research Methodology

A) Primary ResearchOur primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated with Infinium Global Research2. Internal and External subject matter experts3. Professionals and participants from the industry

Our primary research respondents typically include1. Executives working with leading companies in the market under review2. Product/brand/marketing managers3. CXO level executives4. Regional/zonal/ country managers5. Vice President level executives.

B) Secondary ResearchSecondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include1. Company reports and publications2. Government/institutional publications3. Trade and associations journals4. Databases such as WTO, OECD, World Bank, and among others.5. Websites and publications by research agencies

Segment CoveredThe global cell therapy market is segmented on the basis of cell type, therapy type, application, and end-users.

The Global Cell Therapy Market by Cell Type Stem Cell Differentiated Cell

The Global Cell Therapy Market by Therapy Type Allogenic Therapies Autologous Therapies

The Global Cell Therapy Market by Application Autoimmune Diseases Oncology Dermatology Muscoskeletal Therapies Other Applications

The Global Cell Therapy Market by End-Users Hospitals and Clinics Biotechnology and Pharmaceutical Companies Research Institutes

Company Profiles NuVasive, Inc Kolon TissueGene, Inc. JCR Pharmaceuticals Co., Ltd. Osiris Therapeutics, Inc. Stemedica Cell Technologies, Inc. MEDIPOST Celgene Corporation ANTEROGEN.CO., LTD Vericel Corporation

What does this report deliver?1. Comprehensive analysis of the global as well as regional markets of the cell therapy market.2. Complete coverage of all the segments in the cell therapy market to analyze the trends, developments in the global market and forecast of market size up to 2025.3. Comprehensive analysis of the companies operating in the global cell therapy market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.Read the full report: https://www.reportlinker.com/p05796546/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Go here to read the rest:
Global cell therapy market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 - Yahoo Finance

Gary Pesselt: Vitality Healthcare is it worth the cost? – The Union of Grass Valley

Another seminar is again advertised in The Union. I first thought it might help my wife with neuropathy until I did some extensive research.

First off, Medicare does not cover stem cell injections. Bone marrow stem cell injections range from $2,000 to $5,000 or more. Read Consumer Research report at: https://www.consumerreports.org/medical-treatments-procedures/trouble-with-stem-cell-therapy.

Stem cell treatments are widely accepted only for two broad medical indications: to help treat a handful of blood disorders including leukemia and some forms of anemia and in some cases to help burn victims. Ask questions. Any doctor who offers stem cell therapy should be able to explain where the cells will come from, what will be done to them before theyre injected into your body, and how, exactly, they will resolve your illness or injury. He or she should also be able to offer you proof of safety and efficacy, even for experimental treatments. Dont rely on patient testimonials.

Stem cells survive much longer than ordinary cells, increasing the chance that they might accumulate genetic mutations. It might take only a few mutations for one cell to lose control over its self-renewal and growth and become the source of cancer. Please do your own research.

Gary Pesselt

Grass Valley

Follow this link:
Gary Pesselt: Vitality Healthcare is it worth the cost? - The Union of Grass Valley

Stem Cell Banking Market to Witness Robust Expansion throughout the Forecast 2017-2023: : Allied Market Research – GuruFocus.com

Stem cells can repair and self-renewal damaged cells and can thus be used to treat various medical conditions. These cells are stored as they have the potential for usage in the treatment of any medical conditions that the person can further from in the future. The collected stem cells are cryopreserved and stored for decades, which can be later used to treat large number of chronic diseases such as leukemia, thalassemia, and diabetes.

The global stem cell banking market was valued at $1,986 million in 2016, and is estimated to reach $6,956 million by 2023, registering a CAGR of 19.5% from 2017 to 2023. North America is the highest contributor in the stem cell banking market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.

Click Here To Access The Sample Report @ https://www.alliedmarketresearch.com/request-sample/4614

Rise in number of births occurring globally, increase in R&D activities in regards with applications of stem cells, and surge in prevalence of fatal chronic diseases drive the growth of the market. The growth in GDP & disposable income globally is projected to help increase the number of stem cell units stored, which in turn boosts the market growth. However, legal and ethical issues related to stem cell collections and lack of acceptance and awareness in the developing regions are projected to hinder the market growth.

Among the cell type, the umbilical cord stem cell segment dominates the market, as these stem cells can be used to treat almost 80 diseases and the extraction process is easy and does to harm the newborn in any way. However, the adult stem cell segment is expected to register the highest growth rate during the forecast period.

Depending on bank type, the private stem cell banking is the dominant segment in the stem cell banking market. Although the number of public banks are more than private banks, the revenue generated by private stem cell banks are more, which contributes toward the growth of the market.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/4614

Key Findings of the Stem Cell Banking Market:

Used stem cells is projected to grow at the highest rate among the utilization segment during the analysis period.

North America dominated global stem cell banking market in 2016, and is projected to continue its dominance in future.

China is expected to grow at the highest rate in the Asia-Pacific region during the forecast period.

Storage service segment was the largest contributor among the service type segments in 2016.

The private stem cell bank generated the highest revenue, and is expected to continue its dominance in future.

In 2016, North America was the major revenue contributor, owing to increase in awareness toward the benefits of storing stem cell and favorable regulatory scenario. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, due to high birth rate in populace countries such as India and China.

The key players operating in the global stem cell banking market include Cord Blood Registry, ViaCord, Cryo-Cell, China Cord Blood Corporation, Cryo-Save, New York Cord Blood Program, CordVida, Americord, CryoHoldco, and Vita34. Other prominent players in the value chain include Caladrius Biosciences, Cryoviva, Smart Cells International Ltd., Stemade Biotech, Cytori Therapeutics, Cellular Dynamics International, PerkinElmer, and Reelabs.

Obtain Report Details: https://www.alliedmarketresearch.com/stem-cell-banking-market

About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of Market Research Reports and Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesToll Free: +1-800-792-5285UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1(855)550-5975[emailprotected]https://www.linkedin.com/company/allied-market-researchFollow Us on Twitter: https://twitter.com/marketresearcht

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at [emailprotected].

WiredRelease

Visit WiredRelease's Website

The rest is here:
Stem Cell Banking Market to Witness Robust Expansion throughout the Forecast 2017-2023: : Allied Market Research - GuruFocus.com